Program
relmapirazin
Also written as “MB-102”, “Lumitrace” and “MB-102 and commercially available optical angiography imaging system”.
Its studies are mostly in Renal Insufficiency · Retinal Diseases · Blastic Plasmacytoid Dendritic Cell Neoplasm · Renal Insufficiency, Chronic · Acute Kidney Injury, led by 3 companies.
Drug pageRelmapirazin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediBeacon | 62 open or running | phase 3since Apr 21, 2022 | May 10, 2016 | Dec 2026phase 1 · NCT07080008 |
| Huadong Medicineits history only | 10 open or running | phase 3since Mar 22, 2023 | Mar 22, 2023 | none ahead |
| Mustang Bioits history only | 10 open or running | phase 2since Sep 25, 2019 | Sep 25, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of MediBeacon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 10, 2016First study: phase 2 study in Acute Kidney InjuryFirst studyNCT02772276 · 234 enrolled · United States
- Jun 9, 2017Named relmapirazinINNProposed as its International Nonproprietary Name in WHO's List 117 · before, MB-102
- May 22, 20192 early phase 1 studiesNCT04008121, NCT03962998
- Apr 21, 2022Phase 3 study in Renal Insufficiency, ChronicNCT05425719 · 249 enrolled · United States, China
- Mar 8, 2023Phase 3 study in Kidney DiseasesNCT05777174 · 149 enrolled · United States
- Jul 15, 2025Phase 1 study in Ureter InjuryNCT07080008 · 10 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Ureter InjuryNCT07080008
- Dec 2026Primary completion: early phase 1 study in Retinal DiseasesNCT04008121
TargetBeta
“A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA) and ”NCIt, by rule
Other programs on IL3RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pivekimab sunirinerule | AbbVie | phase 3 | 4 |
Studies
All 6 MediBeacon leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07080008Ureter Injury · United States | 1 | Active, not recruiting | Dec 2026 | 10 |
| NCT05777174Kidney Diseases · United States | 3 | Completed | Apr 15, 2024 | 149 |
| NCT05425719Renal Insufficiency, Chronic · United States, China | 3 | Completed | Feb 15, 2023 | 249 |
| NCT04008121Retinal Diseases · United States | Early 1 | Recruiting | Dec 2026 | 10 |
| NCT03962998Crohn Disease · United States | Early 1 | Completed | Oct 5, 2021 | 22 |
| NCT02772276Acute Kidney Injury · United States | 2 | Completed | Aug 4, 2021 | 234 |
How it is read
Names in the registry
- “MB-102”, 4 entries
- “Lumitrace”, 1 entry
- “MB-102 and commercially available optical angiography imaging system”, 1 entry
- “MB-102 OMID”, 1 entry
- “MB-102-- single dose of 4 µmol/kg”, 1 entry
Codes read as this program: MB102.
Conditions, from the studies’ own filings
- Renal Insufficiency, 2 studies
- Retinal Diseases, 1 study
- Blastic Plasmacytoid Dendritic Cell Neoplasm, 1 study
- Renal Insufficiency, Chronic, 1 study
- Acute Kidney Injury, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.